Understanding Hodgkin's Disease
Feb-15-2007
Hodgkin's disease is a type of lymphoma, a cancer affecting the lymphatic system, which defends the body against infection and disease.
Health Tip: Understanding Hodgkin's Disease
(HealthDay)
Feb-15-2007
HealthDay - (HealthDay News) -- Hodgkin's disease is a type of lymphoma, a
cancer affecting the lymphatic system, which defends the body against
infection and disease.
Favrille Hodgkin's drug shows promise
Feb-12-2007
Biopharmaceutical company Favrille has reported promising long-term follow-up data from a phase II trial of FavId, following high dose therapy and autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Seattle Genetics' drugs get a boost
Feb-14-2007
U.S. regulators have granted orphan-drug status to Seattle Genetics' drug candidates for the treatment of leukemia and Hodgkin's disease.
Favrille signs partner in cancer research agreement
Feb-14-2007
Favrille has entered into an agreement with Berlex, a US affiliate of Bayer Schering Pharma, regarding the use of FavId in combination with Leukine in B-Cell non-Hodgkin's lymphoma.
Hodgkin's Disease Treatment Raises Lifelong Heart Risk
Feb-07-2007
Title: Hodgkin's Disease Treatment Raises Lifelong Heart Risk
Category: Health News
Created: 2/8/2007 2:06:00 AM
Last Editorial Review: 2/8/2007
Category: Health News
Created: 2/8/2007 2:06:00 AM
Last Editorial Review: 2/8/2007
Hodgkin's disease therapy ups heart attack risk
(Reuters)
Feb-06-2007
Reuters - Survivors of Hodgkin's lymphoma
are at increased risk of having a fatal heart attack for up to
25 years after undergoing treatment, a British research team
reports.
Hodgkin's disease therapy ups heart attack risk
Feb-07-2007
NEW YORK (Reuters Health) - Survivors of Hodgkin's lymphoma are at increased risk of having a fatal heart attack for up to 25 years after undergoing treatment, a British research team reports.
Risk for Fatal MI Persists 25 Years After Hodgkin's Treatment
Feb-07-2007
Researchers report the increased risk is related to supradiaphragmatic radiotherapy and may also be linked to anthracycline and vincristine treatment.
Medscape Medical News
Allison Gandey
Medscape Medical News
Allison Gandey
Laureate Pharma in Manufacturing Agreement with Trubion Pharmaceuticals
Feb-01-2007
TRU-016 , a novel protein for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia , is designed to target CD37, an antigen present on B cells.
Benefit planned for Lansing survivor of Hodgkin's disease
Feb-02-2007
LANSING - Even workers with full-time jobs and medical insurance may discover that medical expenses can run pretty high.